Moreover, the immunotherapeutic efficacy of several immune checkpoint inhibitors (ICIs) (anti-CTLA4/PD-L1/PD-1, 8) has widely assessed and has achieved a notable response in tumor treatment, including LUAD (12–14). Here, CD274 is linked to neoplasm.